CEPI and Dynavax collaborate to secure adjuvant for COVID-19 vaccines in 2021
01 February 2021, Oslo, Norway — CEPI, the Coalition for Epidemic Preparedness Innovations, and Dynavax Technologies Corporation (Nasdaq: DVAX), today announced an agreement to support the supply of Dynavax's CpG 1018 vaccine adjuvant in 2021 for CEPI-funded COVID-19 vaccine development programmes.
CEPI will provide Dynavax a forgivable loan of up to $99m, recoverable upon product sales, to advance the at-risk manufacture of CpG 1018 in 2021. The adjuvant produced under this agreement will be first offered for purchase by CEPI's vaccine development partners within price parameters agreed with CEPI, and represents a key strategic investment by CEPI to increase overall availability of vaccine doses in 2021 from CEPI's COVID-19 R&D portfolio.
It is anticipated that vaccine developers benefiting from CpG 1018 produced under this agreement will make vaccine output — potentially hundreds of millions of doses in 2021 — available for procurement and allocation through COVAX. COVAX is the global initiative to ensure rapid and equitable access to COVID-19 vaccines for all countries, regardless of income level.
"CEPI's collaboration with Dynavax will help to maximise the number of doses of COVID-19 vaccines available through CEPI's R&D portfolio in 2021. Even though vaccine rollout is underway in some countries, it is clear that demand for vaccines will vastly exceed supply for some time to come. By taking action now, we are securing critical supplies of adjuvant for vaccine developers committed to equitable access through COVAX.”
About CEPI
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines to stop future epidemics. CEPI has moved with great urgency and in coordination with WHO in response to the emergence of COVID-19. CEPI has initiated 11 partnerships to develop vaccines against the novel coronavirus. The programmes will leverage rapid response platforms already supported by CEPI as well as new partnerships. The aim is to advance COVID-19 vaccine candidates into clinical testing as quickly as possible.
Before the emergence of COVID-19 CEPI's priority diseases included Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and Chikungunya virus. CEPI also invested in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (Disease X).
Follow our news page for the latest updates. Follow us on Twitter and LinkedIn.
About COVAX
COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, is co-led by CEPI, Gavi and WHO — working in partnership with developed and developing country vaccine manufacturers, UNICEF, the World Bank, and others. It is the only global initiative that is working with governments and manufacturers to ensure COVID-19 vaccines are available worldwide to both higher-income and lower-income countries.
Media Contacts
CEPI
Email: [email protected]
Phone: +44 7387 055214
Real-world effectiveness of COVID-19 vaccines
The Race to Future-Proof Coronavirus Vaccines
